1. Home
  2. ACHR vs GKOS Comparison

ACHR vs GKOS Comparison

Compare ACHR & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Archer Aviation Inc.

ACHR

Archer Aviation Inc.

HOLD

Current Price

$6.78

Market Cap

5.4B

Sector

Industrials

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$107.89

Market Cap

6.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACHR
GKOS
Founded
2018
1998
Country
Employees
N/A
N/A
Industry
Aerospace
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
6.3B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ACHR
GKOS
Price
$6.78
$107.89
Analyst Decision
Buy
Strong Buy
Analyst Count
7
14
Target Price
$12.14
$132.00
AVG Volume (30 Days)
36.2M
818.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$33.04
Revenue Next Year
N/A
$22.62
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.48
$73.16
52 Week High
$14.62
$161.78

Technical Indicators

Market Signals
Indicator
ACHR
GKOS
Relative Strength Index (RSI) 38.16 40.71
Support Level $6.61 $105.37
Resistance Level $7.57 $115.19
Average True Range (ATR) 0.40 4.91
MACD -0.05 -1.48
Stochastic Oscillator 22.45 11.57

Price Performance

Historical Comparison
ACHR
GKOS

About ACHR Archer Aviation Inc.

Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: